Boekel Scientific, OEM Manufacturers of Medical Equipement.

Amy-Jo takes the reigns as the spotlight is on laboratory research and our equipment as it has been at few times in human history because of vaccine development and treatment research necessitated by the coronavirus pandemic.

PHILADELPHIA (PRWEB)
December 15, 2021

Boekel Scientific, a globally recognized designer and manufacturer of laboratory equipment and medical devices, has announced the promotion of Amy-Jo Yogmas to President, effective immediately. She replaces Stephen Christie, who had served in the role since 2015. Yogmas has 17 years of progressively responsible executive experience at Boekel Scientific in the areas of sales, marketing, quality, and operations. She also last month was nominated to serve as Vice Chairman of the Laboratory Products Association, the leading trade group representing the laboratory products industry, where she has been a member of the Board of Directors since 2019.

“We are delighted to welcome Amy-Jo to the role of President and know from our many years of experience working successfully with her the energy, vision, and knowledge she brings to the role,” said Leo Synnestvedt, Chairman of the Board, Boekel Scientific. “We also want to thank Stephen for his dedicated service and wish him much continuing success,” Leo said. “Amy-Jo takes the reigns as the spotlight is on laboratory research and our equipment as it has been at few times in human history because of vaccine development and treatment research necessitated by the coronavirus pandemic.”

Yogmas assumes leadership of Boekel Scientific with a mandate to fulfill the company vision of global leadership in the supply and innovation of life science tools. “I am honored to lead a company with a world-class team dedicated to fulfilling our mission,” Yogmas said. “We will supply the research and medical communities with high-quality products that will contribute to improving life as our mission states,” she continued. Yogmas is already familiar to many of the company’s associates and will work to enhance and coordinate their efforts in further developing the company and its products.

Specific goals include expanding Boekel Scientific’s research and medical device offerings while coordinating closely with the company’s distributors to benefit patients and researchers. The company defines itself by the life-saving potential of its products and their ability to serve humankind. It drives a continuing emphasis on innovation in product development and unmatched quality standards for all equipment and tools bearing the Boekel Scientific brand name.

About Amy-Jo Yogmas

A native of Bucks County, PA, Yogmas and her husband Ed reside there today. She approaches every aspect of her extensive career at Boekel with enthusiasm and a spirit of professionalism. Whether obtaining Medical Device Manufacturing standard ISO 13485 or understanding the efficiency of thermoelectric cooling, she uses her intelligence and initiative to be decisive and drive innovation further. She also prides herself on empowering her associates, giving them the freedom and room to learn and grow professionally.

Some of her notable achievements at Boekel include obtaining SCOPE approval for its blood banking equipment and managing the development of an OEM blood pathogen detection reagent warming system. She is often visible at Boekel trade show booths demonstrating the capabilities of the company’s highly regarded plasma thawers or CO2 incubators.

About Boekel Scientific

Founded in 1868, Boekel Scientific is an ISO 9001:2008 and ISO 13485:2003 certified company.

It is a globally recognized pioneer in the laboratory products industry. Boekel designs and manufactures a range of lab equipment and medical devices in the United States, renowned for their quality, accuracy, and durability. The company’s product portfolio includes blood banking equipment such as laboratory shakers, platelet storage and plasma thawing equipment, blood collection devices, co2 incubators, tissue flotation baths, laboratory rotators, water baths, dry bath incubators and heaters, UV crosslinkers, and hybridizer ovens. It also custom-builds equipment for clients with unique needs for their reagents and assays.

Share article on social media or email:

The Winter issue of Contentment magazine introduces The Mammalian Stress Mechanism as discovered by Dr. Coleman. Subscriptions are free. Sign up and read about this amazing breakthrough at stress.org

This is the zenith of 20th century science and the most important advance in the history of medicine and biology for the 21st century.

WEATHERFORD, Texas (PRWEB)
December 10, 2021

How do our bodies work? Does science have all those questions answered? Sadly, no. For if they did, medical treatments would have far better outcomes. Medicine is based on flawed and incomplete theories of physiology accepting large gaps in understanding and theoretical fillers to make assumptions seem viable and justify therapies.

Professor Hans Selye, “the father of stress medicine,” had another idea based on his observation that people with widely varying diagnoses exhibited similar symptoms. He coined the term “stress,” in the context of how we use the term today, defining how we react to any demands placed upon our bodies and minds. Although he was a prolific researcher, and founded a new concept of physiology, there wasn’t sufficient science in his day to finish the task replacing putative concepts with known facts.

After working on it for over 20 years, anesthesiologist Dr. Lewis S. Coleman has uncovered the Mammalian Stress Mechanism originally proposed by Hans Selye, explaining how the relationship between illnesses and the environment stress us, and how our bodies naturally respond by repairing us and making us whole again. This Unified Theory of Medicine and Biology explains how treatments that restore normal stress mechanism activity can cure disease and save lives. This is the zenith of 20th century science and the most important advance in the history of medicine and biology for the 21st century.

The Winter issue of Contentment magazine, released today, introduces The Mammalian Stress Mechanism as discovered by Dr. Coleman. Subscriptions are free. Sign up and read about this amazing breakthrough today at the nonprofit American Institute of Stress, at https://www.stress.org/daily-life/contentment-magazine

The stress mechanism is complex, beautiful, and a force of nature. It normally functions efficiently and unobtrusively to supply oxygen and nutrients to cells throughout the body, to maintain and repair tissues when they are injured, regulate blood flow, breathing, digestion and excretion. Combinations of tissue damage and hyperactive nervous system activity overwhelm the stress mechanism causing it to waste the body’s resources and produce excessive and defective substances that damage tissues and disrupt organ function. This manifests as disease.

All the time, money and human toll invested in attempting to cure cancer and so many other diseases made little progress because it was all based on an incomplete and often flawed physiology. Now if medical schools, researchers, and governments embrace and shift resources along the way Dr. Coleman informs us, healthcare in the near future will not only be far more effective, but it will also be kinder, gentler, working with our bodies rather than overpowering us. So called “modern medicine” will languish in history in the way we think of medieval medicine now. Dr. Coleman’s new book is the new bible of medicine and requires and deserves intense study and adoption in every field of healthcare. Dr. Lewis S. Coleman is truly the father of 21st century medicine.

50 Years Lost in Medical Advance: The discovery of Hans Selye’s stress mechanism by Lewis S. Coleman, MD, FAIS, published by the American Institute of Stress Press is available on Amazon and wherever fine books are sold.

“The full implications of this compendious work could well alter all fields of medicine if research based on these ideas bear fruit.” — W.A.C. Mutch, MD, FRCPC, Professor of Anesthesia and Perioperative Medicine, Director Neuroanesthesia Research Laboratory, Kleysen Institute for Advanced Medicine Researcher, Health Sciences Centre at the University of Manitoba.

“The core theory with mechanisms and some practical applications are extremely insightful and should not be missed by anyone interested in their own health or in how our medical and research system is searching in unhelpful domains and applying less than helpful theoretical applications. [Dr. Coleman’s] book and its theory need to find their way into the minds of our current thought leaders and funding recipients and anyone actually trying to reduce human diseases.” — Elliott English, Director of Telehealth Operations for BlueStar Telehealth.

The American Institute of Stress (stress.org) is a non-profit organization established in 1978 at the request of Hans Selye, MD, PhD, by his protégé Paul Rosch, MD to serve as a clearinghouse for information on all stress related subjects. Other founding members included Linus Pauling, Alvin Toffler, Bob Hope, Michael DeBakey, Herbert Benson, Ray Rosenman and other prominent physicians, health professionals and lay individuals interested in exploring the science and multitudinous varied effects of stress on our health and quality of life. Online at Stress.org.

Share article on social media or email:

CHICAGO (PRWEB)
December 09, 2021

Using a process called DNA Sonification, ViroMusic.io has created a collection of 10,000 songs made using the genetic code of the Coronavirus. The team wrote software to comb through the viral code to identify sections that sound musical. The algorithm then turns each letter of RNA into a musical note, comprising a melody. As a final touch, human-played instruments are added on top as accompaniment. The songs are available as an NFT collection on Rarible.com.

Most NFT collections are images of digital art. This makes ViroMusic unique, as it’s a collection of 10,000 songs. The company hopes NFT collectors will snap up the chance to own a unique piece of the code that has shaped so much of our current lives.

From the ViroMusic website: “The idea for this collection was born from an awe of the beauty in the code of life. We hope this project helps to raise awareness that even a virus capable of inflicting such misery is fundamentally based on the same code as every living thing on earth. We thought it would be interesting to take this code and make it play music. We hope you find it as haunting, interesting and provocative as we do.”

While the code in the virus was responsible for creating the unique melody in each song, several musicians helped to make the songs more interesting by playing parts along with the melody. Musicians included Yoed Nir on the cello, whose credits include Regina Spektor, Judy Collins and Interpol’s Paul Banks. Drum parts were added by Chuck Sabo, who recorded on albums by Elton John, XTC, OMD and Natalie Imbruglia.

More info at https://www.viromusic.io

Available of Rarible.com: https://rarible.com/viromusic

Twitter: https://twitter.com/ViroMusicNFT

Video examples of the songs:

https://www.youtube.com/channel/UCzSO7ORrOC3ST92bCPa-yJg

Share article on social media or email:

JUPITER, Fla. (PRWEB)
December 09, 2021

Scheduled to broadcast spring/2022, Advancements with Ted Danson will focus on cutting-edge biomedical technologies for cancer metastasis care.

Hearing from experts in the field, viewers will learn about recent developments in biopharmaceutical technologies. Spectators will see how Cellmig Biolabs (Cellmig) is translating revolutionary discoveries into pioneering medicines and medical devices for terminating cancer lethality, saving cancer patients’ lives, and improving the quality of life of patients worldwide.

Audiences will discover how Cellmig uses novel molecules and biomedicines for the diagnosis of tumor metastasis in very early stage, and for the treatment and therapy of cancers.

“Cellmig uses CCT marker protein-based molecular biomedicine technologies to produce precise and effective diagnosis kits and cancer drugs. Cellmig is producing the next generation cancer prognosis and diagnosis technologies and cancer drugs for the precise and effective cure of cancers” said Tingfang Yi, CEO & President of Cellmig Biolabs.

The show will also explore how Cellmig uses physical membranous cancer cell dissemination pathways of Cytocapsular Tubes in clinical cancer patients and how the revolutionary discovery is fundamental and essential for cancer metastasis therapy and treatment.

“We look forward to sharing how Cellmig is developing next generation medicines that are designed to effectively inhibit cancer cell dissemination and eliminate and terminate cancer,” said Richard Lubin, senior producer for Advancements.    

About Cellmig Biolabs:

Cellmig is a global leading biopharmaceutical company that is committed to translating revolutionary discoveries into pioneering medicines and medical devices for terminating cancer lethality, saving cancer patients’ lives, and improving life quality of patients worldwide.

For more information, visit: http://www.cellmig.com

About Advancements and DMG Productions:

The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit http://www.AdvancementsTV.com or call Richard Lubin at 866-496-4065.

Share article on social media or email:

We are honored that we supported Genesis as its first outside investor and the tremendous progress we made together as partners

DENVER (PRWEB)
December 08, 2021

Rallyday Partners (Rallyday), a Denver-based private equity firm executing its “built by founders for founders” investing strategy, has announced the firm’s first sale. After partnering with the founders of Genesis Research (Genesis) to recapitalize the business on February 28, 2020, completing two add-on acquisitions bringing artificial intelligence technology and a European presence to the platform, and building a world-class team of scientific and business talent, Rallyday completed the transaction with Global Healthcare Opportunities (GHO), a European specialist investor in global healthcare, on November 16, 2021.

Founded in 2009 and headquartered in Hoboken, New Jersey, Genesis is a pioneer in the emerging field of Real-World Evidence (RWE), servicing market leading innovators across the life sciences industry. Genesis optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication, and utilization of integrated Real-World Data (RWD). Genesis has an established footprint in the U.S. and U.K. with more than 120 employees.

Capitalizing on the demand for value demonstration, regulatory agency requirements to reduce the cost of new drug development, and the growing availability of RWD, Genesis Research’s tech-enabled services enable its pharma customers to work faster and better demonstrate drug efficacy. The company’s data-agnostic approach to accessing and analyzing RWE enables utilization of the best data sources available, which includes data drawn from a wide range of sources outside of clinical studies.

The partners at Rallyday, said, “We look for industry tailwinds, innovative business models and ‘monster’ founders who want to elevate their industries with our passionate and systematic approach. As former CEO’s and entrepreneurs, we are deeply proud that Genesis was able to thrive under our ownership. We are also inspired by the entire team at Genesis, led by CEO Frank A. Corvino, who accomplished more in 18 months than most companies achieve in a decade.”

Steve Arikian, Chairman and Co-Founder of Genesis Research, said, “When we first met Rallyday, we knew that we had found our partner. Compared to other investors who were interested in Genesis, the partners at Rallyday were all former entrepreneurs like myself who I could trust to take our company and employees to new levels of possibility with the integrity of a founder. Rallyday exceeded our expectations in every regard and our recent sale is a tribute to everything that is right about partnership done the right way for the right reasons.”

Frank A. Corvino, CEO and Co-Founder of Genesis Research, said: “Our entire team is grateful for Rallyday’s guidance and support. The Rallyday Accelerator Program (RAP) systematically aligned our strategy, refined our culture to support that strategy, and provided a leadership development program that created a fulfilling experience for everyone in our organization. Rallyday’s belief in our team’s potential, coupled with a relationship that was established in foundational trust, empowered us to become the best version of ourselves.”

The partners at Rallyday, concluded: “The hallmark of our work is the creation of win/wins for all stakeholders. We are honored that we supported Genesis as its first outside investor and the tremendous progress we made together as partners. We are elated that GHO will lead Genesis to new levels of positive impact in the life sciences sector and we are humbled that this transaction is supporting the work of our investors who invest on behalf of university endowments and other philanthropic activities.”

Berg Hill Greenleaf Ruscitti, LLP acted as legal advisor to Genesis and Piper Sandler as financial advisor.

More information regarding Rallyday is available at http://www.rallydaypartners.com.

More information regarding Genesis is available at http://www.GenesisRG.com.

More information regarding GHO is available at http://www.ghocapital.com.

Share article on social media or email:

WILMINGTON, Del. (PRWEB)
December 01, 2021

Each year The Scientist seeks to highlight the latest and greatest tools, technologies, and techniques to hit the life science landscape. For more than a decade, we’ve been employing the assistance of expert panels of independent judges who weigh submissions of innovative products speeding work in laboratories and facilitating biological discovery. This year’s crop of entries to The Scientist’s Top 10 Innovations contest reflected the fact that the scientific community, like the whole of society, has been adjusting to a new reality marked by the second year of an extremely challenging and taxing global pandemic. At the same time, work in other areas of the life sciences has preserved. “In a way, it’s heartening that scientific advances have continued to occur in spaces outside of the crucial coronavirus focus,” says Editor-in-Chief Bob Grant. “It suggests that the global biomedical apparatus is robust enough to address a pressing and pointed concern while not losing ground in fields not directly related to that crisis.”

The winners of The Scientist’s Top 10 Innovations of 2021 contest are:

1) nVueTM System (Inscopix) – This “miniaturized microscope” enables dual color imaging of two distinct brain signals in freely-behaving animals, such as two neuronal populations or neural activity in conjunction with brain blood flow.

2) PhysioMimix™ Multi-Organ System (CN Bio) – The microfluidic platform allows scientists to connect individual organ-on-a-chip models for disease research and drug development.

3) MERSCOPETM (Vizgen) – This single-cell spatial genomics instrument, the only one currently available for purchase, detects RNA transcripts from hundreds of genes across intact tissue and returns imaging and expression data at subcellular resolution.

4) Brain-Chip (Emulate) – This organ-on-a-chip model consists of two channels embedded in flexible rubber polymer—one channel represents blood vessel walls and the other represents the brain—and midway along the chip, the two channels come into contact, allowing scientists to study the blood-brain barrier.

5) Gemini and Mark I (Q Bio) – The Mark I prototype scans the entire body using magnetic resonance imaging (MRI), and the imaging results are uploaded to the Gemini platform, along with medical records, genetics data, and traditionally acquired tests of blood, urine, saliva, and vital signs, to create a “digital twin” of the patient.

6) Chromium X (10X Genomics) – Loading cells, reagents, and a partitioning oil into a microfluidic chip, researchers can use this benchtop instrument to create droplets, or Gel Bead-In-Emulsions (GEMs), that each contain a single cell, a single barcoded Gel Bead, and a reagent, and are ready to be sequenced and used in assays offered by 10x Genomics.

7) SARS-CoV-2 Neutralization Assay Development Kits (The Native Antigen Company) – This coronavirus neutralization assay uses synthetic versions of the SARS-CoV-2 spike protein’s receptor binding domain and its target, the mammalian ACE-2 receptor, to quantify a serum sample’s level of antibodies that bind, and therefore neutralize, the virus, as evidenced by a color change.

8) Tapestri Single-cell Multi-omics Solution (Mission Bio) – This process for single-cell analysis allows users to consider DNA sequence and proteomic information simultaneously, and therefore correlated at the single-cell level.

9) CRISPR-SNP-Chip (Cardea Bio) – Equipped with a CRISPR-Cas system tethered to a graphene transistor, this device is the first of its kind that can detect single base differences in DNA without generating millions of copies of the DNA first.

10) Molecular CartographyTM Single-Cell Spatial Analysis Service (Resolve Biosciences) – This mail-in service offers fluorescence in situ hybridization (FISH) to create high-resolution images of individual RNA transcripts inside intact tissues—down to the subcellular level.

Congratulations to this year’s winners. Be sure to visit https://www.the-scientist.com/features/2021-top-10-innovations-69438 where you can read more about the products that earned top spots and see comments from our expert judges.

About The Scientist:

The Scientist is a publication for life science professionals that is dedicated to covering a wide range of biological fields. The Scientist provides print and online coverage of the latest developments in the life sciences, including trends in research, new technology, news, business, and careers. It is read by the science-curious public and leading researchers in industry and academia who value penetrating analyses and broad perspectives on life science topics both within and beyond their areas of expertise. Written by prominent scientists and professional journalists, articles in The Scientist are concise, accurate, accessible, and entertaining.

Share article on social media or email:

Biocompare, a Division of CompareNetworks, Acquires Chromocyte

We are excited to continue the Chromocyte mission of educating and providing resources to the flow cytometry community.

SAN FRANCISCO (PRWEB)
November 23, 2021

CompareNetworks, Inc., a leading provider of online B2B marketplaces for the scientific and healthcare industries, today announced the asset acquisition of Chromocyte Limited, a website that serves the flow cytometry community and market.

Chromocyte will join Biocompare, the life science industry’s leading resource for helping scientists find products for their research. Biocompare is part of CompareNetwork’s extensive portfolio that serves the scientific marketplace.

“Flow cytometry is a key market that Biocompare serves,” said Joan Boyce, Vice President and General Manager of Biocompare. “Biocompare and Chromocyte have complementary missions – educating the flow cytometry community, and for that reason we are excited to continue the Chromocyte mission of educating and providing resources to the flow cytometry community.”

Chromocyte was first developed by Graham Pockley, PhD, Professor of Immunobiology at Nottingham Trent University, as an online tool and resource to make it easier to design panels for flow experiments.

“My research focuses on using tools like multiparameter flow cytometry to understand the immunoregulatory mechanisms underlying disease states,” said Dr. Pockley. “The goal behind developing Chromocyte was to make experimental design easier, and more accurate and reproducible. I am delighted about this acquisition, as Biocompare is the perfect partner to carry on Chromocyte’s mission to educate, enable and improve flow cytometry practice.”

In addition to the website, Chromocyte also publishes a series of email newsletters as well as a ‘sister’ site that focuses on flow cytometry related job openings (http://www.flowcytometryjobs.com). For more information on Chromocyte, visit http://www.chromocyte.com.

Chromocyte

Chromocyte (http://www.chromocyte.com) is an impartial and innovative online resource for designing complex multi-parameter flow cytometry antibody panels and finding the reagents and antibodies that are required for these and other related techniques. Based on the extensive academic background in flow cytometry of its Founder, Chromocyte has been developed to provide invaluable insights into current developments and address specific needs of the academic, research, clinical and commercial flow cytometry communities.

Biocompare

Biocompare (http://www.biocompare.com) is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative resource that enables them to make better product, technology, and service purchasing decisions. Produced by scientists, Biocompare’s mission is to provide free, time-saving services to life science researchers, allowing scientists to find and learn about the technologies that drive discovery. Biocompare continually strives to serve the life science community by providing new and improved online services that facilitate product discovery and technology education.

CompareNetworks, Inc.

CompareNetworks (http://www.comparenetworks.com) operates targeted, online, B2B marketplaces for professionals worldwide. Focused on providing detailed product information for niche markets, CompareNetworks integrates online marketplaces, email newsletters, award-winning video, whitepapers and editorial content to bring buyers and sellers together. With an extensive directory of millions of products and parts with complete specifications and thousands of product videos, CompareNetworks provides the most up-to-date B2B marketplaces on the Web.

Share article on social media or email: